CTOs on the Move

Connect Hearing

www.connecthearing.com

 
We provide a strong network of convenient neighborhood hearing care centers across the country that continually strives to find innovative ways to serve you better. Our Hearing Care Professionals are passionate about helping people to hear better, applying a consistent process to determine the best recommendations for your hearing health. We provide free next day evaluations with professional recommendations based upon your inidiviudal hearing needs and lifestyle. We offer a walk-in, walk-out 2-week FREE trial with hearing aids that are right for you - plus the Connect Advantage, your assurance Connect Hearing will be there every step of the way. Headquartered in the Chicago ...
  • Number of Employees: 0-25
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details
Sven Davies
 Vice President of Information Technology Profile

Similar Companies

Night Shift Radiology

Night Shift Radiology is a San Mateo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Promedica, Int.

Promedica, Int. is a Costa Mesa, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Arizona Pain Relief

Get relief today in the Phoenix Area! We treat whiplash, knee, back, shoulder, joint pain and more! No narcotics, no surgery, just relief!

RandD Medical Products

R&D Medical Products is a Lake Forest, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Synthetic Biologics

Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN". The Company`s principal executive offices are located in Rockville, MD, and the finance and administrative office is located in Ann Arbor, MI. Synthetic Biologics, Inc. is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company`s lead candidates in Phase 2 development include SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat the underlying cause of irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis, and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.